Join the BioNap Email List!

Saturday, August 15, 2015

Should The New Aralez Pharmaceuticals Be In Your Portfolio?

By Jason Napodano, CFA

On August 10, 2015, Pozen Inc. (POZN) reported financial results for the second quarter ending June 30, 2015. Below I briefly comment on the operating results for investors. I then discuss the planned merger with Tribute Pharma (TBUFF), and conclude with what I think the future holds for the new company, to be called Aralez Pharmaceuticals plc, and what I think it's worth on a market value and per share basis.

Please the article on Seeking-Alpha: LINK

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.